Cancer News

Tecentriq™ Plus Abraxane® Effective Combo in Difficult to Treat Breast Cancer (06/30/2016)

The combination of the immune stimulating agent Tecentriq™ (atezolizumab), plus the chemotherapy agent Abraxane® (nab-paclitaxel) is effective in providing anti-cancer responses among patients with advanced triple-negative breast cancer (TNBC). These results were recently reported at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Approximately 10-20% of breast cancers are referred to … Continue reading "Tecentriq™ Plus Abraxane® Effective Combo in Difficult to Treat Breast Cancer"

Directly Involving Patients Drives Participation in Metastatic Breast Cancer Study (06/22/2016)

A clinical study to accelerate research in metastatic breast cancer has rapidly enrolled participants through direct collaboration with patients. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). One large challenge in furthering research in the field of cancer is obtaining enough samples of tumor tissue … Continue reading "Directly Involving Patients Drives Participation in Metastatic Breast Cancer Study"

ASCO Publishes Breast Cancer Survivorship Guidelines (01/25/2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal of Clinical Oncology. There is an estimated 3.1 million breast cancer survivors alive today in the United States. At present, … Continue reading "ASCO Publishes Breast Cancer Survivorship Guidelines"